CureDuchenne Ventures was formed in 2014 after the successful exit from an equity investment in Prosensa (acquired by BioMarin Pharmaceuticals for $680M).
As of 2020, CureDuchenne’s portfolio includes 18 wide-ranging projects with 5 successful exits. Investments from CureDuchenne Ventures have successfully leveraged more than $2.3 billion in follow-on financing from venture capital, biotech, and pharmaceutical companies to fund emerging projects to find treatments for Duchenne.
CureDuchenne Ventures’ impact fund deploys donor dollars to fund Duchenne muscular dystrophy treatments with the singular vision of funding a cure for the entire Duchenne community.
Our robust pipeline of therapies comes from a diverse array of cutting edge technologies used to treat all aspects of Duchenne. CureDuchenne Ventures’ early funding helps Duchenne science attract future investments made by VC firms, biotech companies and pharmaceutical companies.
A successful investment made by CureDuchenne Ventures is a success for the entire Duchenne community. 90% of earnings are re-invested back into Duchenne research to further the goal of a cure.
CureDuchenne Ventures, LLC is the investment arm of CureDuchenne, a national nonprofit dedicated to curing Duchenne muscular dystrophy, the most common and lethal form of muscular dystrophy.
FOUNDED AND FUNDED
developing gene-editing therapies for Duchenne
developing therapies to improve muscle function and enhance steroid tolerance
Collaborative Trajectory Analysis Project:
to enhance Duchenne clinical trial design
a neuromuscular focused CRO to accelerate drug development for Duchenne
acquired UNC vector core, worked to facilitate Pfizer acquisition
a spin-out from USC seeking to develop novel anti-fibrosis therapy
Kevin Flannigan at Nationwide Children’s:
to develop U7 gene therapy to treat rare duplication mutations
a spin-out from Leiden University and assisted subsequent acquisition by BioMarin
when on clinical hold, enabling first Duchenne drug approval by FDA
to encourage development of stop-codon read through drugs
accelerate newborn screening for Duchenne muscular dystrophy
oligonucleotide therapeutics agents for exon skipping to muscle, diaphragm and heart
specialty prescribing application for patients suffering from Duchenne muscular dystrophy
Dyne’s FORCE™ platform enhances the delivery of exon skipping therapeutics to skeletal, cardiac and smooth muscle with the potential to improve efficacy and reduce dosing frequency
Biotech company developing an innovative non-viral gene therapy to deliver full length dystrophin for Duchenne muscular dystrophy (DMD).
CureDuchenne Ventures supports Duchenne research by using philanthropic donations to encourage development of new Duchenne drugs. Through an impact financing model we can provide both grant funding to academic groups, as well as equity financing to biotech and pharmaceutical companies.
100% of proceeds from equity positions in companies are reinvested to support research into next-generation technologies.
Every dollar donated has the ability to fund multiple projects and have a lasting impact on the treatment of Duchenne. Help us create a self-sustaining fund which will redeploy proceeds from exited positions in companies to fund the next-generation of Duchenne research.
CureDuchenne Ventures’ Impact Model of Funding Research
We find, fund and foster early-stage science using philanthropic dollars. We amplify our funding power by exiting our position in companies and reinvesting those returns into emerging scientific research opportunities.
FIND the next stage Duchenne research that needs additional financial support to make it out of the lab to commercialization.
FUND the science with DONOR dollars through grants, loans, or equity financing.
FOSTER development of the technology with:
- In-house company creation and drug development expertise
- Introduction to Duchenne research and clinical resources
- Aligning of strategic partnerships
- Additional capital investments as needed
- Achieve proof-of-concept and find pharma partners at the right time